ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.

We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues.

Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.

Biotechnology

ArrePath

Kurt Thorn

Deidre Johns

Paul Lukacs

Kyle Barbary

Kevin Hare

Graham H.

Erin Chinn

The Leadership Team at ArrePath drives the strategic vision and operational direction of the company, focusing on the application of advanced technologies to combat antimicrobial resistance. With expertise in technology, data science, and scientific advisory, they facilitate innovative drug discovery processes and ensure alignment with the company's mission to develop novel anti-infectives. Their leadership fosters collaboration and guides cross-functional teams in leveraging cutting-edge imaging and AI/ML technologies to deliver impactful solutions for global health challenges.

Leadership Team

Science and Research Team

Board Members and Advisors

Leadership Team

About

Team members

Other teams at ArrePath

Science and Research Team

Board Members and Advisors